Helicobacter pylori vaccine - Provalis

Drug Profile

Helicobacter pylori vaccine - Provalis

Alternative Names: HP0310; Ulsatat

Latest Information Update: 16 May 2007

Price : $50

At a glance

  • Originator Provalis
  • Developer Provalis; University of Newcastle, Australia
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Helicobacter infections

Most Recent Events

  • 17 Feb 2003 Suspended - Preclinical for Helicobacter infections in Australia (PO)
  • 17 Feb 2003 Provalis is seeking to divest of all vaccine programmes not already licensed to third parties
  • 06 Sep 2002 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top